Form 8-K Chime Financial, Inc. For: Jun 02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices and zip code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
Not Applicable | ||||||||
(Former name or former address, if changed since last report) | ||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 5.07 – Submission of Matters to a Vote of Security Holders
On June 2, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Chime Financial, Inc. (the “Company”), the Company’s stockholders voted upon the following proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 17, 2026: (1) to elect three nominees as Class I directors, to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified; (2) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; (3) to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers; and (4) to select, on a non-binding advisory basis, whether future advisory votes on the compensation of the Company's named executive officers should be held every one, two, or three years.
The final voting results with respect to each proposal are as set forth below.
(1) Proposal for the election of three Class I directors:
For | Against | Abstain | Broker Non-Votes | |||||||||||||||||||||||
Christopher Britt | 669,932,083 | 22,666,650 | 115,016 | 120,030,740 | ||||||||||||||||||||||
Shawn Carolan | 691,382,248 | 1,170,676 | 160,825 | 120,030,740 | ||||||||||||||||||||||
James Dunne | 667,719,395 | 24,832,777 | 161,577 | 120,030,740 | ||||||||||||||||||||||
Based on the votes set forth above, each director nominee was duly elected to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.
(2) Proposal to ratify Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:
For | Against | Abstain | ||||||||||||
812,274,646 | 316,594 | 153,249 | ||||||||||||
Based on the votes set forth above, the stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
(3) Proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers:
For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
685,837,192 | 6,658,614 | 217,943 | 120,030,740 | |||||||||||||||||
Based on the votes set forth above, the stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.
(4) Proposal to select, on a non-binding advisory basis, whether future advisory votes on the compensation of the Company’s named executive officers should be held every one, two, or three years:
1 Year | 2 Years | 3 Years | Abstain | Broker Non-Votes | ||||||||||||||||||||||
691,498,616 | 17,654 | 209,974 | 987,505 | 120,030,740 | ||||||||||||||||||||||
Based on the votes set forth above, the stockholders advised that they were in favor of every one year as the frequency of holding a non-binding advisory vote on named executive officer compensation. Based on the results of the vote, and consistent with the recommendation of the Company’s Board of Directors (the “Board”), the Board has determined to hold a non-binding advisory vote regarding named executive officer compensation every one year until the next required non-binding advisory vote on the frequency of holding future votes regarding named executive officer compensation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Chime Financial, Inc. | |||||||||||
June 4, 2026 | By: | /s/ Adam Frankel | |||||||||
Name: | Adam Frankel | ||||||||||
Title: | General Counsel and Corporate Secretary | ||||||||||
ATTACHMENTS / EXHIBITS
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Form 8.3 - [ANIMALCARE GROUP PLC - 19 06 2026] - (CGWL)
- CSG showcased new projects, partnerships and key portfolio products at Eurosatory 2026
- Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share